Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.

Climent N, Guerra S, García F, Rovira C, Miralles L, Gómez CE, Piqué N, Gil C, Gatell JM, Esteban M, Gallart T.

PLoS One. 2011;6(5):e19644. doi: 10.1371/journal.pone.0019644. Epub 2011 May 18.

2.

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.

Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M Jr, Lifson JD, Picker LJ.

Nature. 2011 May 26;473(7348):523-7. doi: 10.1038/nature10003. Epub 2011 May 11.

3.

Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Rehm KE, Roper RL.

Vaccine. 2011 Apr 12;29(17):3276-83. doi: 10.1016/j.vaccine.2011.02.023. Epub 2011 Feb 23.

4.

The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Girgis NM, Dehaven BC, Xiao Y, Alexander E, Viner KM, Isaacs SN.

J Virol. 2011 Mar;85(6):2547-56. doi: 10.1128/JVI.01474-10. Epub 2010 Dec 29.

5.

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.

Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA.

PLoS One. 2010 Nov 15;5(11):e13983. doi: 10.1371/journal.pone.0013983.

6.

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M.

PLoS One. 2010 Aug 24;5(8):e12395. doi: 10.1371/journal.pone.0012395.

7.

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M.

PLoS One. 2010 Jun 30;5(6):e11406. doi: 10.1371/journal.pone.0011406.

8.

Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Guerra S, González JM, Climent N, Reyburn H, López-Fernández LA, Nájera JL, Gómez CE, García F, Gatell JM, Gallart T, Esteban M.

J Virol. 2010 Aug;84(16):8141-52. doi: 10.1128/JVI.00749-10. Epub 2010 Jun 9.

9.

Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.

Aboud S, Nilsson C, Karlén K, Marovich M, Wahren B, Sandström E, Gaines H, Biberfeld G, Godoy-Ramirez K.

Clin Vaccine Immunol. 2010 Jul;17(7):1124-31. doi: 10.1128/CVI.00008-10. Epub 2010 May 12.

10.
11.

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa, Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD.

PLoS One. 2010 Jan 25;5(1):e8816. doi: 10.1371/journal.pone.0008816.

12.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.

Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.

PMID:
19943789
13.

Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7.

Oda S, Schröder M, Khan AR.

Structure. 2009 Nov 11;17(11):1528-37. doi: 10.1016/j.str.2009.09.005.

14.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

15.

Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.

Esteban M.

Hum Vaccin. 2009 Dec;5(12):867-71. Epub 2009 Dec 3. Review.

PMID:
19786840
16.

The interferon system and vaccinia virus evasion mechanisms.

Perdiguero B, Esteban M.

J Interferon Cytokine Res. 2009 Sep;29(9):581-98. doi: 10.1089/jir.2009.0073. Review.

PMID:
19708815
17.

Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings.

Zhang L, Villa NY, Rahman MM, Smallwood S, Shattuck D, Neff C, Dufford M, Lanchbury JS, Labaer J, McFadden G.

J Proteome Res. 2009 Sep;8(9):4311-8. doi: 10.1021/pr900491n.

18.

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.

Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T.

PLoS Pathog. 2009 Jun;5(6):e1000480. doi: 10.1371/journal.ppat.1000480. Epub 2009 Jun 19.

19.

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.

Gómez CE, Nájera JL, Sánchez R, Jiménez V, Esteban M.

Vaccine. 2009 May 21;27(24):3165-74. doi: 10.1016/j.vaccine.2009.03.049. Epub 2009 Apr 8.

PMID:
19446187
20.

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X, Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD, Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG, Erickson S, Allison DB, Piatak M Jr, Lifson JD, Shiver JW, Casimiro DR, Shaw GM, Hahn BH, Watkins DI.

J Virol. 2009 Jul;83(13):6508-21. doi: 10.1128/JVI.00272-09. Epub 2009 Apr 29.

Supplemental Content

Support Center